Denise Myshko

CMS has no plans to change their coverage and approval process, which the Alzheimer's Association believes is standing between patients and treatment.

At the upcoming hearing, the committee will examine the impact of PBMs on access to healthcare and the Pharmacy Benefit Manager Transparency Act which was submitted by Sens. Maria Cantwell and Chuck Grassley.

New approvals include gene therapies, first-in-class drugs, treatments for rare diseases, and cancer, as well as biosimilars.

The Medicare Part D Senior Savings Model — a CMS effort to test $35 copays for insulin — led to lowered total costs for beneficiaries.

Seven of the 10 top selling drugs with high price increases lack the clinical evidence to justify those increases.

A confirmatory trial of Tecentriq in urothelial carcinoma failed to meet the co-primary endpoint of overall survival.

Omnipod DASH PDMs are at increased risk of malfunction if overcharged beyond the maximum battery voltage.

Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.

However, researchers found that only a small percentage of plans use available real-world evidence studies and economic evaluations in their coverage policies.

Hospitalization, disability, having private high-deductible, Medicare Advantage, or no coverage were risk factors associated with medical debt.

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

Survey participants said their drug costs have gone up and almost a third had trouble paying for food and housing because of high drug costs.

A meta-analysis has found that depression and anxiety are significantly correlated with dry eye disease symptoms but not to dry eye disease signs.

A literature review finds that glaucoma care changed for the better during the COVID-19 pandemic.

The drug is a potential new therapy for dry eye disease with a novel mechanism of action.

As Congress considers legislation that would cap out-of-pocket costs for insulin, Walmart and Civica Rx are taking steps that could make less expensive versions of the diabetes medication more available.

Collaboration among stakeholders is needed to increase transparency of pharmacy payment programs and to better align the design of these models with good patient care.

Collaboration among stakeholders can increase transparency of pharmacy payment programs and better align the design of these models with enhanced patient care.